CRIS Current Research Information System

ANDRINI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.228
NA - Nord America 902
EU - Europa 729
AF - Africa 98
SA - Sud America 81
OC - Oceania 4
Totale 4.042
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 876
CN - Cina 623
VN - Vietnam 606
SG - Singapore 531
IT - Italia 283
HK - Hong Kong 162
KR - Corea 105
DE - Germania 80
NL - Olanda 65
IN - India 62
BR - Brasile 59
SE - Svezia 55
GB - Regno Unito 44
FI - Finlandia 35
IE - Irlanda 33
JP - Giappone 33
CI - Costa d'Avorio 31
FR - Francia 31
CH - Svizzera 24
RU - Federazione Russa 22
TG - Togo 21
CA - Canada 15
ID - Indonesia 14
JO - Giordania 14
TH - Thailandia 14
ZA - Sudafrica 14
SC - Seychelles 13
PH - Filippine 12
AT - Austria 11
BG - Bulgaria 10
TW - Taiwan 10
MX - Messico 9
BD - Bangladesh 8
IQ - Iraq 7
PL - Polonia 7
TR - Turchia 7
AR - Argentina 5
MA - Marocco 5
AU - Australia 4
CL - Cile 4
EC - Ecuador 4
LT - Lituania 4
EG - Egitto 3
ES - Italia 3
GR - Grecia 3
HU - Ungheria 3
LB - Libano 3
NG - Nigeria 3
PK - Pakistan 3
SA - Arabia Saudita 3
UA - Ucraina 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CO - Colombia 2
DZ - Algeria 2
HR - Croazia 2
LV - Lettonia 2
MY - Malesia 2
NP - Nepal 2
PY - Paraguay 2
TN - Tunisia 2
VE - Venezuela 2
AL - Albania 1
BE - Belgio 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GF - Guiana Francese 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LY - Libia 1
MK - Macedonia 1
MT - Malta 1
PE - Perù 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
Totale 4.042
Salva come PNG Salva come JPEG
Città #
Singapore 380
Hefei 217
Ashburn 176
Ho Chi Minh City 169
Hong Kong 149
Hanoi 138
San Jose 122
Seoul 99
Santa Clara 83
Bologna 68
Beijing 57
Boardman 34
Chandler 34
Dublin 33
Abidjan 31
Los Angeles 26
Tokyo 26
Council Bluffs 25
Helsinki 25
Milan 25
Dong Ket 24
Bern 22
Fairfield 22
Lomé 21
Dallas 20
Bengaluru 19
Vicenza 19
Biên Hòa 18
Da Nang 18
Shanghai 18
Frankfurt am Main 17
Haiphong 17
Lauterbourg 17
Munich 16
Buffalo 15
New York 14
Amman 13
Southend 13
Turin 12
Hyderabad 11
Amsterdam 10
Guangzhou 10
Johannesburg 10
Sofia 10
Nuremberg 9
Princeton 9
Quận Bình Thạnh 9
Redondo Beach 9
Tongling 9
Chicago 8
Falkenstein 8
Houston 8
Hải Dương 8
Montreal 8
São Paulo 8
Woodbridge 8
Wuhan 8
Can Tho 7
Jakarta 7
Lappeenranta 7
London 7
Seattle 7
Tianjin 7
Brooklyn 6
Bến Tre 6
Ha Long 6
Hangzhou 6
Mexico City 6
Rome 6
Thái Bình 6
Vienna 6
Düsseldorf 5
Orem 5
Shenzhen 5
Wilmington 5
Bangkok 4
Bensalem 4
Bình Phước 4
Florence 4
Istanbul 4
Modena 4
Mumbai 4
Ninh Bình 4
Phoenix 4
Poplar 4
Redmond 4
Shijiazhuang 4
Thu Dau Mot 4
Warsaw 4
Xi'an 4
Atlanta 3
Baghdad 3
Brasília 3
Bristol 3
Bắc Giang 3
Cambridge 3
Chengdu 3
Chennai 3
Elk Grove Village 3
Ferrara 3
Totale 2.612
Salva come PNG Salva come JPEG
Nome #
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 232
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review 191
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 190
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 184
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors 166
Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients 165
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 160
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 159
Bone targeting agents in patients with metastatic prostate cancer: State of the art 157
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 157
Endoscopic Ultrasound-Guided Locoregional Treatments for Pancreatic Neuroendocrine Neoplasms 157
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 155
An Update on Appendiceal Neuroendocrine Tumors 153
Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading? 136
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 133
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 132
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 123
Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population-based analysis 117
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET) 113
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges 112
β1600 Q.Clear Digital Reconstruction of [68Ga]Ga-DOTANOC PET/CT Improves Image Quality in NET Patients 94
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 80
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 78
Challenges and future perspectives for the use of temozolomide in the treatment of SCLC 77
Non-small-cell lung cancer: how to manage RET-positive disease 74
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 73
BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: A case report and review of the literature 72
Safety and cost-effectiveness of immediate right hemicolectomy versus active surveillance for well-differentiated appendiceal neuroendocrine tumors 1-2 cm in size: a Markov decision analysis 63
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1-2 cm 59
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 58
Antibody–drug conjugates for lung cancer in the era of personalized oncology 50
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 42
Determinants of incidence trends in pancreatic neuroendocrine neoplasms 37
Multifocal paraneoplastic encephalitis associated with anti-GABA-B and anti-Hu antibodies manifesting with status epilepticus and epilepsia partialis continua: Expanding the clinical-radiological spectrum 36
Baseline neuronal antibodies in patients with small cell lung cancer are not necessarily associated with post-immune checkpoint inhibitors neurotoxicities 35
ARTEMIS: a pilot study comparing AI-based and expert therapeutic decisions in simulated clinical cases of neuroendocrine neoplasms 33
Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoids 32
Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer 31
Updates on Pulmonary Neuroendocrine Carcinoids: Progress and Perspectives 23
Totale 4.139
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.049
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.049
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202139 0 0 0 0 0 0 0 0 0 5 6 28
2021/2022110 0 0 2 4 8 3 3 19 10 6 40 15
2022/2023346 12 28 8 13 15 25 30 32 73 25 34 51
2023/2024158 9 17 6 12 9 35 13 19 6 16 9 7
2024/2025939 49 56 76 64 119 54 61 44 25 82 86 223
2025/20262.473 269 396 190 189 203 102 339 115 493 177 0 0
Totale 4.139